Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 17/20 | 0.44 |
| ▸ | MPEG1 | Q2M385 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | XIAP | P98170 | 2/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311908 | 1.00 | MAPT (0.65) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL1186913 | 1.00 | MAPT (0.65) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL21854615 | 1.00 | MAPT (0.65) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL1187732 | 1.00 | MAPT (0.65) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL12134627 | 1.00 | MAPT (0.65) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL14894797 | 0.98 | MAPT (0.61) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL15695040 | 0.91 | MAPT (0.53) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL9578634 | 0.91 | MAPT (0.52) | MAPTTDP1ALDH1A1THRBALOX5 | |
| SCHEMBL14030869 | 0.89 | MAPT (0.54) | MAPTTDP1ALDH1A1THRBCYP2C9 | |
| SCHEMBL1188401 | 0.89 | MAPT (0.54) | MAPTTDP1ALDH1A1THRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344142-B1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS INC (US) | 2024-06-26 | — | — | EP | claimed |
| CN-118175991-A | Pharmaceutical composition comprising 2,3, 5-trimethyl-6-nonylcyclohexa-2, 5-diene-1, 4-dione | PTC医疗公司 | 2024-06-11 | — | — | CN | claimed |
| EP-4366700-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE | PTC Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| WO-2024050725-A1 | METHODS OF PRODUCING 2, 3, 5, 6-ALKYL-1, 4-BENZOQUINONES | PTC THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| WO-2024054871-A1 | METHODS OF PRODUCING 2,3,5,6-ALKYL-1,4-BENZOQUINONES | PTC THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| US-20240000725-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE | PTC THERAPEUTICS INC (US) | 2024-01-04 | — | — | US | claimed |
| US-20230339835-A1 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | PTC THERAPEUTICS, INC. | 2023-10-26 | — | — | US | claimed |
| EP-4257190-A2 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | PTC Therapeutics, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| US-11746077-B2 | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | PTC THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | claimed |
| US-11667596-B2 | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | PTC THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | claimed |
| US-20220106248-A1 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | PTC THERAPEUTICS, INC. | 2022-04-07 | — | — | US | claimed |
| US-11174212-B2 | 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | PTC THERAPEUTICS, INC. (US) | 2021-11-16 | — | — | US | claimed |
| US-20210276937-A1 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | PTC THERAPEUTICS, INC. | 2021-09-09 | — | — | US | claimed |
| CN-113365616-A | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1, 4-diones for the inhibition and treatment of alpha-synucleinopathies, tauopathies and other diseases | PTC医疗公司 | 2021-09-07 | — | — | CN | claimed |
| WO-2020081879-A2 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | PTC THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | claimed |
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | claimed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | claimed |
| EP-2344142-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | Edison Pharmaceuticals, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010030607-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | WO | claimed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | MAPT 112/4885TDP1 253/4885ALDH1A1 108/4885 |
| US-11667596-B2 | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | SNCA, MAPT, TARDBP | MAPT 2/4885TDP1 144/4885ALDH1A1 355/4885 |
| US-11174212-B2 | 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | TARDBP, UBQLN2, SNCA | MAPT 5/4885TDP1 55/4885ALDH1A1 266/4885 |
| US-20230339835-A1 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | SNCA, MAPT, TARDBP | MAPT 2/4885TDP1 144/4885ALDH1A1 355/4885 |
| US-11746077-B2 | 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders | SNCA, MAPT, TARDBP | MAPT 2/4885TDP1 144/4885ALDH1A1 355/4885 |
| US-20240000725-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE | SYNCRIP, SNCA, MAPT | MAPT 3/4885TDP1 163/4885ALDH1A1 135/4885 |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | MAPT 112/4885TDP1 253/4885ALDH1A1 108/4885 |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | MAPT 112/4885TDP1 253/4885ALDH1A1 108/4885 |
| US-20210276937-A1 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | SNCA, MAPT, TARDBP | MAPT 2/4885TDP1 144/4885ALDH1A1 355/4885 |
| US-20220106248-A1 | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | SNCA, MAPT, TARDBP | MAPT 2/4885TDP1 144/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.